COVID-19 and ICU-acquired MDR Bacteria

NCT04378842 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 368

Last updated 2026-04-22

No results posted yet for this study

Summary

This multicenter before-after study aimed to determine the impact of infection related to SARS-CoV-2 on the incidence of ICU-acquired multidrug resistant (MDR) bacteria.

Conditions

  • Sars-CoV2
  • Critical Illness

Sponsors & Collaborators

  • University Hospital, Lille

    lead OTHER

Principal Investigators

  • Saad Nseir, MD,PhD · University Hospital, Lille

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-18
Primary Completion
2021-07-26
Completion
2021-07-26

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04378842 on ClinicalTrials.gov